Sharekhan

Ajanta Pharma Ltd

Thu 13/03/2025,15:57:39 NSE: AJANTPHARM

₹ 2538.25 -6.80 (-0.27%)
BUY NOW Buy Ajanta Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Ajanta Pharma Ltd

Thu 13/03/2025,0:0:0

Ajanta Pharma Ltd

Thu 13/03/2025,15:57:39 | NSE : AJANTPHARM

₹ 2538.25-6.80 (-0.27%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2540.05

Previous Close

₹ 2545.05

Volume

90634

Mkt Cap ( Rs. Cr)

₹31705.81

High

₹ 2595.00

Low

₹ 2526.10

52 Week High

₹ 3485.00

52 Week Low

₹ 1998.35

Book Value Per Share

₹ 294.36

Dividend Yield

2.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Ajanta Pharma Ltd

Your Vote -

Buy

88.69%

Hold

9.49%

Sell

1.82%

88.69%

769 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

2538.25

5

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

5

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Ajanta Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Ajanta Pharma Lt - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Feb 2025, 4:29PM Ajanta Pharma Limited has informed the Exchange about Participation in Investor Conference

  • Ajanta Pharma Lt - Participation In Investor Conference

    20 Feb 2025, 4:24PM PFA Intimation w.r.t Participation in Investor Conference.

  • Ajanta Pharma Lt - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Feb 2025, 9:38AM Ajanta Pharma Limited has informed the Exchange about Participation in Investor Conference

  • Ajanta Pharma Lt - Participation In Investor Conference

    7 Feb 2025, 9:33AM PFA herewith Intimation of Participation in Investor Conference

  • Ajanta Pharma Lt - Integrated Filing- Financial

    5 Feb 2025, 4:41PM PFA Integrated Filing- Financials for the quarter ended 31st December 2024

  • Ajanta Pharma Lt - Updates

    5 Feb 2025, 4:24PM Ajanta Pharma Limited has informed the Exchange regarding 'Grant of Stock Appreciation Rights'.

  • Ajanta Pharma Lt - Integrated Filing (Financial)

    5 Feb 2025, 4:39PM PFA herewith Integrated Filing (Financials)

  • Ajanta Pharma Lt - Grant Of Stock Appreciation Rights

    5 Feb 2025, 4:18PM PFA Intimation w.r.t Grant of Stock Appreciation Rights

  • Ajanta Pharma Lt - Rumour Verification - Regulation 30(11)

    4 Feb 2025, 9:55AM Ajanta Pharma Limited has informed the Exchange about Rumour Verification - Regulation 30(11)

  • Ajanta Pharma Lt - Rumour verification - Regulation 30(11)

    4 Feb 2025, 9:54AM PFA Intimation of Market Price Movement

  • Ajanta Pharma Lt - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Feb 2025, 4:26PM Ajanta Pharma Limited has informed the Exchange about Transcript

  • Ajanta Pharma Lt - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    3 Feb 2025, 4:24PM PFA Written Transcript of Earnings Call conducted on 30th January 2025.

  • Ajanta Pharma Lt - Copy of Newspaper Publication

    31 Jan 2025, 12:58PM Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication

  • Ajanta Pharma Lt - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jan 2025, 6:15PM Ajanta Pharma Limited has informed the Exchange about Link of Recording

  • Ajanta Pharma Lt - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Jan 2025, 6:13PM PFA Audio recording of Earnings call conducted on 30th January 2025

  • Ajanta Pharma Lt - General Updates

    30 Jan 2025, 3:45PM Ajanta Pharma Limited has informed the Exchange about Cancellation of ESOPs

  • Ajanta Pharma Lt - Outcome of Board Meeting

    30 Jan 2025, 3:37PM Ajanta Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on January 30, 2025.

  • Ajanta Pharma Lt - Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St Decembe

    30 Jan 2025, 3:35PM PFA Results of 31st Dec 2024.

  • Ajanta Pharma Lt - Financial Result Updates

    30 Jan 2025, 3:35PM Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.

  • Ajanta Pharma Lt Q3 net profit up 14.67% at Rs 252.45 cr

    30 Jan 2025, 5:20PM The company reported standalone net profit of Rs 252.45 crore for the quarter ended December 31, 2024 as compared to Rs 220.15 crore in the same perio

  • Ajanta Pharma Lt - Cancellation Of Employee Stock Options

    30 Jan 2025, 3:42PM Cancellation of ESOPs

  • Ajanta Pharma Lt - Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For The Quart

    30 Jan 2025, 3:38PM PFA enclosed outcome of Board Meeting for more details.

  • Ajanta Pharma Lt - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Jan 2025, 2:36PM Ajanta Pharma Limited has informed the Exchange about Schedule of meet

  • Ajanta Pharma Lt - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Jan 2025, 2:33PM PFA Intimation of analysts/institutional investors meet.

  • Ajanta Pharma Lt - Board Meeting Intimation

    17 Jan 2025, 2:24PM AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Jan-2025 to inter-alia consider and approve the Unaudited Financi

  • Ajanta Pharma Lt - Board Meeting Intimation for Approving Unaudited Financial Results For The Quarter Ended 31St December 202

    17 Jan 2025, 2:16PM AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 ,inter alia, to consider and a

  • Ajanta Pharma Lt - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Jan 2025, 4:38PM Ajanta Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Ajanta Pharma Lt has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    7 Jan 2025, 4:50PM As of December 2024, 66.26% is owned by Indian Promoters and 33.74% by Public. <p align=justify> Institutional holds 26.28% (Insurance Companies 1.48%

  • Ajanta Pharma Lt - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jan 2025, 4:36PM PFA Certificate under Reg 74(5) of SEBI (DP) Regulations.

  • Ajanta Pharma Lt - Trading Window-XBRL

    27 Dec 2024, 4:27PM AJANTA PHARMA LIMITED has informed the Exchange about Closure of Trading Window

  • Ajanta Pharma Lt - Trading Window

    27 Dec 2024, 4:26PM Ajanta Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 20

  • Ajanta Pharma

    3 May 2024 , 9:59AM Ajanta Pharma reported healthy set of 4QFY24 numbers led by 20% YoY revenue growth of Rs 1054 crs , EBITDA grew by 26% YoY to Rs 278 crs and PAT grew by 19% YoY to Rs 203 crs. EBITDA Margin reported at 26% for 4QFY24 as against 17% in 4QFY23. The company has proposed offer for Buy-back of up to 10,28,881 Equity Shares of the Company at the price of ₹ 2,770/- per Equity Share representing 0.8% of the equity share. The record date for the buyback is May 30th. (Positive)

  • Ajanta Pharma

    31 Aug 2023 , 10:48AM The company has received final approval from US FDA for Topiramate extended release capsules. It is used for epilepsy migraines. It may launch the drug as per settlement terms on Feb 01, 2026 or earlier.

  • Ajanta Pharma

    3 Jul 2023 , 10:24AM Ajanta Pharma is striving to enhance its presence across select geographies with high growth potential such as Asia and Africa for its branded generics as per its Annual report FY2023. The company's branded generics business accounted for ~73% of its revenues in FY2023, with Indian, rest of Asia and Africa contributing 31%, 26% and 15%, respectively. As a part of the efforts towards the target, the company has increased its product filings by three times and enhanced team size by 50% in the rest of Asia and Africa markets. Positive for the stock. We do not have coverage on the stock.

  • Ajanta Pharma

    26 Jun 2023 , 12:24PM The company informed that its Dahej formulation facility was inspected by the USFDA from June 19-June 23, and it got concluded without any form 483 issued. Positive read through for the stock.

  • Ajanta Pharma board approves share buyback

    10 Mar 2023 , 11:28AM Ajanta Pharma board approves share buyback up to Rs. 315 cr at Rs. 1,425/sh via tender route

  • Ajanta Pharma

    8 Mar 2023 , 12:04PM Ajanta Pharma will consider a proposal for a share buyback on March 10.

  • Ajanta Pharma

    15 Jun 2022 , 10:01AM Ajanta Pharma: As per media news, the company gets US-FDA approval for its ANDA for Topiramate, used to treat epilepsy & migraine. Positive read thru

  • Ajanta Pharma surges on share buyback nod

    28 Dec 2021 , 12:45PM Ajanta Pharma rises over 7% to Rs. 2,338.1, as board approves share buyback of 11.2 lakh shares

  • Ajanta Pharma gains on buyback proposal

    24 Dec 2021 , 1:29PM Ajanta Pharma to consider a proposal for share buyback

  • Ajanta Pharma

    24 Dec 2021 , 11:17AM The meeting of the board of directors is scheduled on 28th December 2021 to consider a proposal for the Buy Back of equity shares. As of quarter ending September 2021, the company has a strong cash balance (including investments) of Rs 594 cr. Positive read thru

  • Ajanta Pharma

    22 Jan 2021 , 9:49AM As per media reports, the company has received the approval from the USFDA for Lamotrigine, which is an anti-epilepsy drug. The approval is positive as it could add to the US sales.

  • Ajanta Pharma

    8 Dec 2020 , 10:35AM Ajanta Pharma gets US FDA nod for Tetrabenzine, used to treat chorea associated with Huntington's Disease. The approval is positive as it would widen the product offerings for the company.

  • Ajanta Pharma

    4 Jun 2020 , 10:20AM As per media report the company gets US FDA approval for Doxycycline Hyclate. It is used to treat a wide variety of bacterial infections. Positive as this would add to the US business growth.

  • Ajanta Pharma

    1 Jun 2020 , 9:42AM As per media reports, gets US FDA nod for flu drug Oseltamivir Phosphate. This is positive as it would add to the US business growth.

  • Ajanta Pharma

    22 May 2020 , 10:04AM As per media news, gets USFDA approval for Tolterodine Tartrate. The drug is used for treatment of overactive bladder. Positive as this would add to the US business growth

  • Ajanta Pharma gains on USFDA nod for cholesterol drug

    9 Apr 2020 , 12:02PM Ajanta Pharma rises over 13% to Rs. 1,550, after receiving USFDA nod for Cholestyramine Powder

  • Ajanta Pharma

    15 Jan 2020 , 10:29AM As per media news, the company has received an approval from the USFDA for Valganciclovir Hydrochloride. Valganciclovir is used in adults to prevent infection with cytomegalovirus (CMV) that may occur after an organ transplant (heart, kidney, or pancreas). Valganciclovir is also used to treat CMV infection of the eye in adults with acquired immunodeficiency syndrome. Positive read thru

  • Ajanta Pharma

    8 Jan 2020 , 10:43AM As per media news the company has received an approval from US FDA for Valganciclovir Hydrochloride. The drug is used to prevent infection from cytomegalovirus (CMV) in adults that may occur after an organ transplant and also it is used to treat CMV infection of the eye in adults with acquired immunodeficiency syndrome. Positive

  • Ajanta Pharma promoters sell small stake worth 3.07%

    12 Jul 2017 , 11:03AM Ajanta Pharma announces that company’s promoters sell 27,00,000 equity shares in APL, representing about 3.07% of APL's equity shares
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Ajanta Pharma Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 3413.57 3246.45 3169.18 2884.98 2461.3
Liabilities 3413.57 3246.45 3169.18 2884.98 2461.3
Equity 25.27 25.27 17.17 17.39 17.54
Gross Profit 1119.43 699.28 890.89 916.91 532.78
Net Profit 807.24 558.72 719.86 675.64 441.13
Cash From Operating Activities 735.35 736.29 542.34 466.99 300.88
NPM(%) 20.32 16.37 22.92 24.85 20.08
Revenue 3971.12 3411.27 3140.64 2718.59 2196.42
Expenses 2851.69 2711.99 2249.75 1801.68 1663.64
ROE(%) 21.95 15.19 19.57 18.37 11.99

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
08 Feb 2024 26 1300 2.01 2185.05
04 Aug 2023 10 500 2.01 1511.75
04 Aug 2023 15 750 2.01 1425
09 Nov 2021 9.5 475 2.01 2150.7
12 Nov 2020 9.5 475 2.01 1609.05
15 Nov 2019 13 650 2.01 1004.45
09 Nov 2018 9 450 2.01 1011
23 Mar 2017 7 350 2.01 1763.8
07 Nov 2016 6 300 2.01 1971.3
17 Mar 2016 8 400 2.01 1425.8
25 Jun 2015 6 300 2.01 1263.9
24 Jul 2014 10 200 2.01 1060.55
18 Jul 2013 6.25 125 2.01 777.8
28 Jun 2012 7.5 75 2.01 538.2
29 Jun 2010 3.5 35 2.01 195.85
30 Jun 2009 2.5 25 2.01 63.1
27 Jun 2008 2.5 25 2.01 104.1
19 Sep 2007 2 20 2.01 79.05
18 Sep 2006 1.5 15 2.01 75.35
17 Dec 2002 0 15 2.01 49.85
05 Sep 2001 0 15 2.01 79.4

Peers

Other companies within the same industry or sector that are comparable to Ajanta Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 1450.28 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 5284.65 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 2723.91 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 4982.97 -239.30 0.00

Company Info

2005 -Max Healthcare to establish India`s first brain lab in New Delhi -Max India Ltd Max telecom ventures Ltd signed a MoU 2008 -Max India signs agreement with UK firm for health insurance biz 2012 -Board declares Interim Dividend of 500% i.e. Rs. 10/- for every equity share of Rs. 2/- each to the shareholders. -Ajanta Pharma Ltd has splits its face value from Rs 10/- to 5/- 2013 - Board recommends Final Dividend 610% amounting to Rs. 12.20 per equity share of Rs. 2/- each to the shareholders. -Ajanta Pharma has announces bonus in the ratio of 1:2 2014 -Board recommends Final Dividendof 90%, i.e., Rs. 1.80 for every equity share of Rs. 2/- each to the shareholders 2015 -Ajanta Pharma Announces the Launch of Montelukast Sodium Oral Granules -Launch of Montelukast lR Tablets and Montelukast Chewable Tablets in US market -Fortune India presents award to Ajanta Pharma -Ajanta Pharma gets approvals for 3 ANDA's -Ajanta Pharma has splits its face value from Rs. 5 to Rs. 2 2017 -Ajanta Pharma gets USFDA nod for Duloxetine Hydrochloride. -Ajanta Pharma launches Eletriptan Hydrobromide Tablets. -Ajanta Pharma launches Clonidine Hydrochloride Extended Release Tablets in US. -Inaugurated & commissioned 1st phase at a New Facility in Guwahati, Assam, India - Dahej facility receives successful US FDA approval. 2018 -Top Export Performer Award' by the Federation of Indian Export Organisations. -Commissioned Ajanta's 1st ever Derma facility in Guwahati. 2019 -Ajanta Pharma USA Inc. (APUI) received DIANA award for `Best Overall Generic Manufacturer' in less than $100 mn. -New manufacturing facility for oral solid inaugurated at Pithampur. 2020 -Ajanta's 1st Sterile Eye Drop Production Unit commissioned at Guwahati Facility. 2021 -Listed in Fortune 500 list of Indian companies Ranked 379th in Revenue Generation (Dec 2021). 2022 -The Company has issued Bonus Shares in the Ratio of 1:2. -Ajanta Pharma awarded 'India's Best Managed Companies' for 2022 by Deloitte. -Ajanta wins 'Maharashtra State Best Employer Brand Awards 2022' in Pharma sector -Ajanta wins Excellence in Packaging Developed in India & Packaging Team of the Year at India Packaging Awards 2022 2023 The Company has infomed that, in its meeting scheduled on 10/03/2023 ,inter alia, to consider and approve the proposal for buyback of the equity shares of the Company and matters related / incidental thereto. -Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category -Ajanta wins 'Excellence in Pharma Supply Chain Management - Ajanta wins Times Ascent Global Best Employer Brands 2023 2024 -Ajanta Pharma Certified as a great place to work in India for the 2nd year.

2005 -Max Healthcare to establish India`s first brain lab in New Delhi -Max India Ltd Max telecom ventures Ltd signed a MoU 2008 -Max India signs agreement with UK firm for health insurance biz 2012 -Board declares Interim Dividend of 500% i.e. Rs. 10/- for every equity share of Rs. 2/- each to the shareholders. -Ajanta Pharma Ltd has splits its face value from Rs 10/- to 5/- 2013 - Board recommends Final Dividend 610% amounting to Rs. 12.20 per equity share of Rs. 2/- each to the shareholders. -Ajanta Pharma has announces bonus in the ratio of 1:2 2014 -Board recommends Final Dividendof 90%, i.e., Rs. 1.80 for every equity share of Rs. 2/- each to the shareholders 2015 -Ajanta Pharma Announces the Launch of Montelukast Sodium Oral Granules -Launch of Montelukast lR Tablets and Montelukast Chewable Tablets in US market -Fortune India presents award to Ajanta Pharma -Ajanta Pharma gets approvals for 3 ANDA's -Ajanta Pharma has splits its face value from Rs. 5 to Rs. 2 2017 -Ajanta Pharma gets USFDA nod for Duloxetine Hydrochloride. -Ajanta Pharma launches Eletriptan Hydrobromide Tablets. -Ajanta Pharma launches Clonidine Hydrochloride Extended Release Tablets in US. -Inaugurated & commissioned 1st phase at a New Facility in Guwahati, Assam, India - Dahej facility receives successful US FDA approval. 2018 -Top Export Performer Award' by the Federation of Indian Export Organisations. -Commissioned Ajanta's 1st ever Derma facility in Guwahati. 2019 -Ajanta Pharma USA Inc. (APUI) received DIANA award for `Best Overall Generic Manufacturer' in less than $100 mn. -New manufacturing facility for oral solid inaugurated at Pithampur. 2020 -Ajanta's 1st Sterile Eye Drop Production Unit commissioned at Guwahati Facility. 2021 -Listed in Fortune 500 list of Indian companies Ranked 379th in Revenue Generation (Dec 2021). 2022 -The Company has issued Bonus Shares in the Ratio of 1:2. -Ajanta Pharma awarded 'India's Best Managed Companies' for 2022 by Deloitte. -Ajanta wins 'Maharashtra State Best Employer Brand Awards 2022' in Pharma sector -Ajanta wins Excellence in Packaging Developed in India & Packaging Team of the Year at India Packaging Awards 2022 2023 The Company has infomed that, in its meeting scheduled on 10/03/2023 ,inter alia, to consider and approve the proposal for buyback of the equity shares of the Company and matters related / incidental thereto. -Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category -Ajanta wins 'Excellence in Pharma Supply Chain Management - Ajanta wins Times Ascent Global Best Employer Brands 2023 2024 -Ajanta Pharma Certified as a great place to work in India for the 2nd year.

Read More

Parent Organisation

Ajanta Pharma Ltd.

Founded

31/12/1979

Managing Director

Mr.Yogesh M Agrawal

NSE Symbol

AJANTPHARMEQ

FAQ

The current price of Ajanta Pharma Ltd is ₹ 2538.25.

The 52-week high for Ajanta Pharma Ltd is ₹ 2595.00 and the 52-week low is ₹ 2526.10.

The market capitalization of Ajanta Pharma Ltd is currently ₹ 31705.81. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Ajanta Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Ajanta Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Ajanta Pharma Ltd shares.

The CEO of Ajanta Pharma Ltd is Mr.Yogesh M Agrawal, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT